{
    "name": "Factor X, human",
    "comment": "Rx",
    "other_names": [
        "Coagadex"
    ],
    "classes": [
        "Coagulation Factors",
        "Hemostatics"
    ],
    "source": "https://reference.medscape.com/drug/coagadex-factor-x-human-1000033",
    "pregnancy": {
        "common": [
            "There are no data with factor X concentrate use in pregnant women to inform on drug-associated risk",
            "Animal reproduction studies have not been conducted",
            "It is not known whether factor X concentrate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity",
            "Should be given to a pregnant woman only if clearly needed"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Unknown if distributed in human breast milk",
            "Consider the developmental and health benefits of breastfeeding along with the motherâ€™s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Documented life-threatening hypersensitivity to factor X, human or its components"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Allergic-type hypersensitivity reactions may occur (eg, anaphylaxis, angioedema, infusion site inflammation, chills, cough, dizziness, fever, flushing, generalized urticaria, headache, hives, hypotension, lethargy, musculoskeletal pains, nausea, pruritus, rash, restlessness, tachycardia, tightness of the chest, tingling, vomiting, wheezing); discontinue product immediately and administer appropriate emergency treatment",
                "Formation of neutralizing antibodies (inhibitors) to factor X may occur; if expected factor X activity levels are not attained, or if bleeding is not controlled with an expected dose, perform an assay that measures factor X inhibitor concentration",
                "Transmission of infectious agents may occur; the product is derived from human blood, and despite measures to screen and inactivate/remove certain viruses, it may carry risk of transmitting infectious agents (eg, viruses, the variant Creutzfeldt-Jakob disease [vCJD] agent and, theoretically, the Creutzfeldt-Jakob disease [CJD] agent)",
                "Monitor plasma factor X activity and monitor for factor X inhibitors",
                "Caution when coadministered with other plasma products that may contain factor X (eg, fresh frozen plasma, prothrombin complex concentrates)",
                "Based on the mechanism of action, factor X, human is likely to be counteracted by direct and indirect factor Xa inhibitors (eg, apixaban, edoxaban, dabigatran)"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "antithrombin alfa",
            "description": {
                "common": "antithrombin alfa will decrease the level or effect of Factor X, human by  pharmacodynamic antagonism. Avoid or Use Alternate Drug. Based on the mechanism of action, Factor X is likely to be counteracted by direct and indirect Factor Xa inhibitors."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "antithrombin III",
            "description": {
                "common": "antithrombin III will decrease the level or effect of Factor X, human by  pharmacodynamic antagonism. Avoid or Use Alternate Drug. Based on the mechanism of action, Factor X is likely to be counteracted by direct and indirect Factor Xa inhibitors."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "apixaban",
            "description": {
                "common": "apixaban will decrease the level or effect of Factor X, human by  pharmacodynamic antagonism. Avoid or Use Alternate Drug. Based on the mechanism of action, Factor X is likely to be counteracted by direct and indirect Factor Xa inhibitors."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "argatroban",
            "description": {
                "common": "argatroban will decrease the level or effect of Factor X, human by  pharmacodynamic antagonism. Avoid or Use Alternate Drug. Based on the mechanism of action, Factor X is likely to be counteracted by direct and indirect Factor Xa inhibitors."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bivalirudin",
            "description": {
                "common": "bivalirudin will decrease the level or effect of Factor X, human by  pharmacodynamic antagonism. Avoid or Use Alternate Drug. Based on the mechanism of action, Factor X is likely to be counteracted by direct and indirect Factor Xa inhibitors."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dalteparin",
            "description": {
                "common": "dalteparin will decrease the level or effect of Factor X, human by  pharmacodynamic antagonism. Avoid or Use Alternate Drug. Based on the mechanism of action, Factor X is likely to be counteracted by direct and indirect Factor Xa inhibitors."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "desirudin",
            "description": {
                "common": "desirudin will decrease the level or effect of Factor X, human by  pharmacodynamic antagonism. Avoid or Use Alternate Drug. Based on the mechanism of action, Factor X is likely to be counteracted by direct and indirect Factor Xa inhibitors."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "edoxaban",
            "description": {
                "common": "edoxaban will decrease the level or effect of Factor X, human by  pharmacodynamic antagonism. Avoid or Use Alternate Drug. Based on the mechanism of action, Factor X is likely to be counteracted by direct and indirect Factor Xa inhibitors."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "enoxaparin",
            "description": {
                "common": "enoxaparin will decrease the level or effect of Factor X, human by  pharmacodynamic antagonism. Avoid or Use Alternate Drug. Based on the mechanism of action, Factor X is likely to be counteracted by direct and indirect Factor Xa inhibitors."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fondaparinux",
            "description": {
                "common": "fondaparinux will decrease the level or effect of Factor X, human by  pharmacodynamic antagonism. Avoid or Use Alternate Drug. Based on the mechanism of action, Factor X is likely to be counteracted by direct and indirect Factor Xa inhibitors."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "heparin",
            "description": {
                "common": "heparin will decrease the level or effect of Factor X, human by  pharmacodynamic antagonism. Avoid or Use Alternate Drug. Based on the mechanism of action, Factor X is likely to be counteracted by direct and indirect Factor Xa inhibitors."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rivaroxaban",
            "description": {
                "common": "rivaroxaban will decrease the level or effect of Factor X, human by  pharmacodynamic antagonism. Avoid or Use Alternate Drug. Based on the mechanism of action, Factor X is likely to be counteracted by direct and indirect Factor Xa inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fresh frozen plasma",
            "description": {
                "common": "Factor X, human, fresh frozen plasma.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Caution is advised in patients who are receiving other plasma products that may contain Factor X, (eg, fresh frozen plasma, prothrombin complex concentrates)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prothrombin complex concentrate, human",
            "description": {
                "common": "Factor X, human, prothrombin complex concentrate, human.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Caution is advised in patients who are receiving other plasma products that may contain Factor X, (eg, fresh frozen plasma, prothrombin complex concentrates)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "red blood cells",
            "description": {
                "common": "Factor X, human, red blood cells.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Caution is advised in patients who are receiving other plasma products that may contain Factor X, (eg, fresh frozen plasma, prothrombin complex concentrates)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "washed red blood cells",
            "description": {
                "common": "Factor X, human, washed red blood cells.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Caution is advised in patients who are receiving other plasma products that may contain Factor X, (eg, fresh frozen plasma, prothrombin complex concentrates)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "whole blood",
            "description": {
                "common": "Factor X, human, whole blood.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Caution is advised in patients who are receiving other plasma products that may contain Factor X, (eg, fresh frozen plasma, prothrombin complex concentrates)."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Infusion site erythema",
            "percent": "5.6"
        },
        {
            "name": "Fatigue",
            "percent": "5.6"
        },
        {
            "name": "Back pain",
            "percent": "5.6"
        },
        {
            "name": "Infusion site pain",
            "percent": "5.6"
        }
    ]
}